Consistent Safety and Tolerability Profile Confirmed for Erleada

Recent comprehensive evaluations and ongoing post-marketing surveillance have confirmed Erleada’s consistent and manageable safety profile. Commonly observed side effects such as fatigue, rash, falls, fractures, hypothyroidism, and gastrointestinal discomfort remain consistent with previous clinical and real-world observations. The rare incidence of seizures (~0.2%) continues to align with earlier reported data. Vigilance regarding fall and fracture risks in elderly patients is emphasized, with routine monitoring and preventive measures recommended to manage these risks effectively. No significant new safety concerns have emerged, underscoring the predictability and manageability of Erleada’s side-effect profile.

Citation: Wikipedia, July 2025. Available at: https://en.wikipedia.org/wiki/Apalutamide

Implication: A stable safety profile supports ongoing, confident use of Erleada in clinical practice.